Changes in Hong Kong stocks | Gloria Young (06821) rose nearly 3% in the morning. Recently, Gloria Biotech's Shanghai Fengxian base was officially put into operation, focusing on joint pharmaceutical NDCs and other fields

The Zhitong Finance App learned that Gloria Ying (06821) rose nearly 3% in the morning. As of press release, it had risen 2.05% to HK$79.65, with a turnover of HK$15.517,500.

According to news, recently, according to Gloria Incorporated's official WeChat account, Gloria Biotech's Shanghai Fengxian commercial production base was officially put into operation. This base is another core commercial industrial base that Gloria has focused on building after the Shanghai Jinshan base and the Zhangjiang Science and Technology Center, which can help customers quickly promote commercial production. The commercialization of the Fengxian base means that Gloria Biotech has achieved a leapfrog upgrade in the biopharmaceutical CDMO field.

According to reports, the Fengxian base has a total planned construction area of over 130,000 square meters, focusing on biopharmaceuticals such as conjugated drugs NDCs (Novel Drug Conjugates), antibody/TCE, and recombinant proteins represented by ADC. Antibody commercial production capacity (phase I stage A) uses advanced automation systems and production equipment, equipped with a 200L/500L/2000L disposable bioreactor production line and a 20㎡ freeze-dryer, which can undertake IND and post-commercial projects. The commercial production capacity of NDCs (phase I phase B) is expected to be commercialized in January 2026. It is equipped with a 100L-200L-500L coupling reactor and a 10㎡ +15m+2x20㎡ freeze-dryer, which can quickly and flexibly meet customer production needs.